Advancements in Nanofiltration Technology Will Drive the Viral Clearance Market

Pune, India, 2020-Jan-29 — /EPR Network/ —

The key factors driving the growth of this Viral Clearance Market includes growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nanofiltration technology, and the high incidence and large economic burden of chronic diseases.

According to the new market research report “Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) – Global Forecasts to 2023” published by MarketsandMarkets™

Revenue Growth of the Market:

The Global Viral Clearance Market is expected to reach $724.5 million by 2023 from USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period.

Download PDF (Please provide your specific interest in this report so as to help you better.): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=62681197

Market Segmentation:

On the basis of application, the global market is segmented into four categories recombinant proteins, blood and blood products, vaccines, and other applications. In 2018, the recombinant proteins segment is expected to account for the largest share of the viral clearance market owing to the high potential of recombinant proteins to treat various diseases, fewer side effects, and shorter development time as compared to small molecules. Furthermore, the regulatory requirement to demonstrate the capacity of the purification process to effectively clear infectious viruses during the manufacturing of recombinant proteins is also expected to support the growth of this market segment during the forecast period.

By end user, the market is segmented into pharmaceutical & biotechnology companies, CROs, academic research institutes, and other end users. In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the rapid expansion of the biopharmaceutical industry, growth in the number of research activities in life sciences, increasing R&D investments in drug development, and increasing number of drug launches.

On the basis of method, the viral clearance market is segmented into viral removal and viral inactivation. In 2018, the viral removal segment is expected to account for the largest share of the global market due to the growth in biopharmaceutical R&D activities; the high acceptance of this method; and the accuracy, speed, and flexibility provided by the method in life sciences research.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=62681197

Geographical Analysis:

The North American region is expected to account for the largest share of the market in 2018. However, Asia Pacific is expected to witness the highest growth during the forecast period, owing to increase in generics development and manufacturing, surge in funding for medical research and the presence of a large number of CROs to provide preclinical and clinical research services in China, government initiatives to boost the use of generic drugs, increasing aging population in Japan, rise in pharmaceutical R&D expenditures in India, and the growing pharmaceutical manufacturing in Singapore and Malaysia.

Major Key Players In Global Viral Clearance Market:

Wuxi Biologics (Cayman) (China), Merck KGaA (Germany), Charles River Laboratories International Inc. (US), and Texcell Inc. (France), Kedrion (Italy), Vironova Biosafety (Sweden), Clean Cells (France), BSL BIOSERVICE Scientific Laboratories Munich GmbH (Germany), and ViruSure GmbH (Austria).